Orgenesis (NASDAQ: ORGS) shares are trading higher on Wednesday.
The company announced a cell-based vaccine platform targeting COVID-19 and other existing and emerging viral diseases.
Orgenesis is a biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization.
Orgenesis shares were trading up 14.84% at $6.92 at time of publication on Wednesday. The stock has a 52-week high of $8.20 and a 52-week low of $2.35.